Related Experiment Videos
11q23 rearrangements in acute leukemia
J E Rubnitz1, F G Behm, J R Downing
1Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Leukemia
|January 1, 1996
Summary
Chromosomal rearrangements involving the MLL gene at 11q23 are common in acute leukemias, leading to MLL fusion proteins. These rearrangements are linked to poor prognosis and specific clinical features in patients.
Area of Science:
- Genetics
- Molecular Biology
- Oncology
Background:
- The Mixed Lineage Leukemia (MLL) gene, located at chromosome 11, band q23, is a critical gene in hematopoiesis.
- Chromosomal rearrangements involving the MLL gene are frequently observed in various types of acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Purpose of the Study:
- To review the structural characteristics of MLL fusion proteins resulting from 11q23 translocations.
- To summarize the clinical manifestations associated with MLL gene rearrangements in acute leukemias.
- To discuss the molecular diagnostic approaches for identifying MLL rearrangements.
Main Methods:
- Literature review of studies focusing on MLL gene rearrangements.
- Analysis of structural features of MLL fusion proteins.
- Compilation of clinical data and diagnostic strategies for MLL-rearranged leukemias.
Main Results:
- 11q23 translocations generate specific MLL fusion proteins containing the N-terminus of MLL.
- MLL rearrangements are associated with distinct clinical presentations and a poor prognosis in both ALL and AML.
- Understanding the structural and functional aspects of these fusion proteins is crucial for leukemogenesis.
Conclusions:
- MLL gene rearrangements are significant drivers of leukemogenesis, producing oncogenic fusion proteins.
- Accurate molecular diagnosis and understanding of clinical features are essential for managing MLL-rearranged acute leukemias.
- Further research into MLL fusion proteins may reveal therapeutic targets.